Curzion Pharmaceuticals Acquired by Horizon Therapeutics

Researchers report a key step for the first gene test aimed at reducing unnecessary angiograms — expensive and somewhat risky procedures that hundreds of thousands of Americans have each year to check for clogged arteries. Most of these exams, done in hospital cardiac catheterization labs, turn out negative.